Key Takeaways
- Revenue beat, profit absorbed by tax: FY22 revenue grew 30% YoY to ₹1,557 crores, but PAT grew only 5% because the company became a tax-paying entity for the first time in 25-30 years, incurring a ₹25 crores tax charge.
- Q4 margin collapsed to ~5%: Operating margin fell from a 7-10% historical range to ~5% in Q4, driven by raw material cost increases, a mix shift toward lower-margin domestic API sales, advertising investments, and an appraisal impact. Management calls Q4 an aberration and expects to maintain last year's average margins, not the Q4 margins.
- Working capital consumed all cash: Despite ~₹130 crores in EBITDA, cash from operations was negative ₹58 crores because ₹168 crores was absorbed by trade receivables and inventory. The zero-debt constraint means growth is funded entirely from profits, starving CAPEX.
- Medical devices growth is decelerating: The segment grew 46% for the full year but was heavily skewed to H1 (88% growth during the COVID second wave); H2 saw only 9-10% nominal growth, and the company is holding large inventories of cyclical oxymeters and oxygen concentrators that may incur losses if not disposed of in next few quarters.
- What to watch next quarter: Whether inventory and receivables release cash as promised, whether margins recover from the Q4 trough, and whether Fexofenadine US exports and Sitagliptin (going off-patent in July) begin to contribute materially.
Revenue Growth & Segment Mix
- Broad-based growth, API-led: FY22 revenue of ₹1,557 crores was driven by strong performance across all segments, with domestic revenue growing 38% and export revenue growing 17%. The export share in API consequently dropped from 67% to 64%.
- API domestic surge: Indian domestic API market grew 48%, adding almost ₹100 crores in domestic sales, primarily driven by Montelukast used for asthma and pollution-related conditions.
- API US market rebound: US market grew 48% YoY driven by resumed buying post-COVID travel restrictions, traditional products Loratadine and Montelukast, and new Fexofenadine supplies that started in Q4 after US FDA approval.
- Formulation business recovery: Formulation grew 28% to ₹169 crores, but the high growth rate partly reflects a low base because the previous year had only 5% growth due to COVID impact; the business has now recovered to original numbers.
- OTC milestone crossed: Dr. Morepen OTC grew 23% to ₹106 crores, with trade growing 10% and online growing 273% (now 19% of OTC sales). The Dr. Morepen brand topline reached ~₹685 crores, 36% growth.
- Quarterly revenue pattern: Q1 and Q2 were exceptionally strong due to aggressive customer purchasing during the second COVID wave across retail, B2B, API, and medical devices; Q3 was ₹399 crores; Q4 was slightly lower at ₹372 crores but still near the ₹400 crores quarterly run-rate.
Sushil Suri: "for the first time almost after 25-30 years, the company has started paying tax and we are a tax paying company, we have paid Rs. 25 crores tax this year."
Margin Pressure & Cash Flow
- Q4 margin breakdown: Operating margin fell to ~5% from a 7-10% historical range because raw material costs increased ~5% from supply disruption and China cargo costs, the domestic API mix (especially Montelukast) carried lower profitability, the company invested in advertisement and marketing (Boman Irani, Kareena ads for devices), and an appraisal impact hit in Q4.
- Montelukast margin drag: Montelukast grew 65%, but the growth came mostly from the domestic market, which is less profitable. Management acknowledged this explicitly: "domestic markets are not that profitable, so we have to have some compromise in the margins which is obvious in our results."
- Cash flow negative despite EBITDA: Cash from operations was negative ₹58 crores because ₹68 crores went into trade receivables and ₹100 crores into inventory, totaling ₹168 crores invested into these two working-capital items. Receivables rose due to more domestic business; inventory was built in both diagnostics and API segments to ensure supply chain continuity.
- Zero-debt constraint on growth: Growth of 30% drove working capital up by 25-30%, but the company has no bank borrowings and depends only on profits, so cash is absorbed by working capital rather than CAPEX. Banks are not encouraging lending because of the CDR tag and preference-capital situation and the company is not in a mood for heavy interest rates.
- Margin recovery expectation: Management is confident of maintaining last year's average margins, not the Q4 margins; Q4 was an aberration due to appraisals. Previous quarters had been 7-8%, ranging 8-10%.
Sushil Suri: "Montelukast is sold in the domestic market as you would appreciate domestic markets are not that profitable, so we have to have some compromise in the margins which is obvious in our results"
Medical Devices: Growth Deceleration & Inventory Risk
- Full-year growth masks H2 slowdown: Medical devices grew 46% YoY to ₹419 crores, but growth was heavily skewed to H1 (88% growth during the COVID second wave); H2 saw only 9-10% nominal growth.
- Core products dominate: Glucometers (59% YoY) and BP monitors remain the core business; other products contribute only ~10%. BP monitors crossed 0.1 crore meters sold for the first time, reaching 0.19 crore meters.
- Cyclic product inventory overhang: Large inventories of oxymeters and oxygen concentrators were built during the second wave; the company is holding them in case COVID returns, but may incur losses if not disposed of in the next few quarters.
- International expansion on hold: International markets are on the cards and the facility already has ISO 13485 certification, but international certification audits were stopped due to COVID. It will take at least 2 to 3 quarters before export business restarts in earnest; currently exporting small quantities to Nepal where no approvals are required.
Key Products & Market Share
| Product | FY22 Performance | Commentary |
|---|---|---|
| Montelukast | ▲ 65% growth | Driven by domestic market; export market share rose from 30% to 49.2%. Domestic sales are less profitable, creating margin pressure. |
| Loratadine | ▬ 1% growth | Global market slowed due to mask usage and vaccination reducing flu/allergies; decline in first two quarters was recovered in the next two. Export market share out of India rose to 68% from 60%. |
| Atorvastatin | ▲ 18% growth | Steady contributor. |
| New molecules | ▲ 689% growth | On a very small base; some products under patent with small R&D shipments ongoing. |
| Fexofenadine | New launch | US exports commenced in Q4 after November US FDA approval; 70% of Fexofenadine is export. Approximate contribution ~₹14-15 crores in Q4. |
- Sitagliptin opportunity: Going off patent in July; company already has technology, processes, and tie-ups ready and will be free to sell after July. Management declined to comment further because the product is still under patent.
- Market share strategy: Management frames competitive pricing not as a compromise but as a necessity: "I won't use the word compromise, I would say that we have to be competitive in the market."
Balance Sheet & Capital Structure
- Working capital build: Debtors turnover increased to 1.70 months (from 1.63) due to higher sales and slightly lower recovery. Inventory turnover improved to 4.65 months (from ~5).
- Warrant subscription: Promoters subscribed to ₹2.8 crores shares via warrants, increasing capital by 6%. Remaining warrants have a window until mid-September for conversion; proceeds will primarily fund working capital, with some portion going to ongoing CAPEX.
- Dividend contingent on preference share conversion: The company expects stock exchange approval for preference share conversion any time; once converted and the technical default is cleared, the company will be free to distribute dividend. A board meeting after that clarity will take the call; dividend policy to be decided at the forthcoming AGM.
Sushil Suri: "We are proud to say we are a zero-debt company, we do not have any borrowings. Normally, what happens is in case our has grown by 30%, so there is an increase in working capital by 30%, if not 30, maybe 25%. So, our growth is a big constraint because we are depending only on the profits and that is why we do not have even less CAPEX because whatever we are investing that is going to the working capital."
Regulatory & Competitive Position
- Clean regulatory record: The company has never received a negative feedback, warning letter, or product recall from US FDA; history of NIL 483. Plant is approved by US FDA, EDQM, PMDA Japan, KFDA, EUGMP, and PGA Australia.
- IP and R&D base: 140 patents filed, 130 DMFs, 13 drug licenses in China, 33 new products developed by R&D.
- Customer base expansion: 183 new customers added without much travel or marketing effort, bringing total to 1,009 satisfied customers globally.
- Travel and market reactivation: With COVID slowing and travel resuming, the company has extensive travel plans for the coming 2 years to reactivate and focus on markets and continents that have underperformed. Teams are being expanded in all continents to support growth.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Margin recovery | Maintain last year's average margins, not the Q4 margins | FY23 |
| Cash flow release | Inventory will ease out; both debtors and inventory will release cash flow | Q1 FY23 |
| Fexofenadine US ramp-up | Supplies to US have started and will contribute to continued US growth | Ongoing from Q4 FY22 |
| Sitagliptin launch | Free to sell after patent expiry; technology, processes, and tie-ups ready | July 2022 |
| Medical devices export restart | International certification audits may resume; facilities ready for inspection | 2-3 quarters before export business restarts |
| Warrant conversion | Remaining warrants will be converted | Before September 2022 |
| Dividend decision | Board to take call after preference share conversion clarity; policy at AGM | Forthcoming AGM |
| Near-term stabilization | Numbers to stabilize and return to desired growth trajectory | One or two quarters more |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue | ₹372 cr, +28% YoY |
| Full-year revenue | ₹1,557 cr, +30% YoY |
| Full-year PBT | +29% YoY |
| Full-year PAT | +5% YoY; ₹25 cr tax incidence on ₹126 cr profit |
| Full-year EBITDA | ₹130 cr, +13% YoY |
| Cash from operations | Negative ₹58 cr (full year); ₹168 cr invested in receivables and inventory |
| Operating margin | ~5% (Q4), down from ~8% in Q3 and 10–11% earlier; full-year 7.66% vs 8.36% |
| Net margin | Down ~150 bps (full year) |
| API segment revenue | ₹235 cr, +37% YoY; full-year +26% to ₹863 cr (per an analyst's math) |
| Medical devices segment revenue | ₹419 cr (full year), +46% YoY; Q4 growth ~10% |
| Formulations segment revenue | ₹169 cr (full year), +28% YoY; Q4 +34% |
| OTC segment revenue | ₹106 cr (full year), +23% YoY |
| Dr. Morepen brand topline | ₹685 cr (full year), +36% |
| Export revenue | ₹557 cr (full year), +17% YoY; Q4 +39% |
| Domestic revenue | +38% YoY (full year); Q4 +20% |
| API export share | 64%, down from 67% |
| Montelukast revenue growth | +65% YoY (full year) |
| Loratadine export market share | 68% (out of India), up from 60% |
| Montelukast export market share | 49.2%, up from 30% |
| Glucometers revenue | ₹279 cr (full year), +59% YoY; 0.22 cr meters installed this year |
| BP monitors revenue | ₹84 cr (full year); 0.19 cr meters sold |
| Debtors turnover | 1.70 months, up from 1.63 months |
| Inventory turnover | 4.65 months, down from ~5 months |
| R&D spend | +34% YoY (full year) |